UA83474C2 - Замещенные производные 1-пиперидин-3-ил-4-пиперидин-4-ил-пиперазина и их применение в качестве антагонистов нейрокинина - Google Patents
Замещенные производные 1-пиперидин-3-ил-4-пиперидин-4-ил-пиперазина и их применение в качестве антагонистов нейрокинина Download PDFInfo
- Publication number
- UA83474C2 UA83474C2 UAA200505307A UA2005005307A UA83474C2 UA 83474 C2 UA83474 C2 UA 83474C2 UA A200505307 A UAA200505307 A UA A200505307A UA 2005005307 A UA2005005307 A UA 2005005307A UA 83474 C2 UA83474 C2 UA 83474C2
- Authority
- UA
- Ukraine
- Prior art keywords
- aai
- disorders
- aza
- bibiove
- seiai
- Prior art date
Links
- SQPXSXKACBJSEG-UHFFFAOYSA-N 1-piperidin-3-yl-4-piperidin-4-ylpiperazine Chemical class C1CCNCC1N1CCN(C2CCNCC2)CC1 SQPXSXKACBJSEG-UHFFFAOYSA-N 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title 1
- 230000003042 antagnostic effect Effects 0.000 abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 5
- 208000035475 disorder Diseases 0.000 abstract 4
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 4
- 208000019901 Anxiety disease Diseases 0.000 abstract 2
- 102000003141 Tachykinin Human genes 0.000 abstract 2
- 206010047700 Vomiting Diseases 0.000 abstract 2
- 230000000903 blocking effect Effects 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 108060008037 tachykinin Proteins 0.000 abstract 2
- 208000027932 Collagen disease Diseases 0.000 abstract 1
- 206010012335 Dependence Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 101001125071 Homo sapiens Neuromedin-K receptor Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000021891 Micturition disease Diseases 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 125000000815 N-oxide group Chemical group 0.000 abstract 1
- 208000007920 Neurogenic Inflammation Diseases 0.000 abstract 1
- 101800000399 Neurokinin A Proteins 0.000 abstract 1
- 102400000097 Neurokinin A Human genes 0.000 abstract 1
- HEAUFJZALFKPBA-YRVBCFNBSA-N Neurokinin A Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)O)C1=CC=CC=C1 HEAUFJZALFKPBA-YRVBCFNBSA-N 0.000 abstract 1
- 102000009493 Neurokinin receptors Human genes 0.000 abstract 1
- 108050000302 Neurokinin receptors Proteins 0.000 abstract 1
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 abstract 1
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 abstract 1
- 108010040722 Neurokinin-2 Receptors Proteins 0.000 abstract 1
- 102100029409 Neuromedin-K receptor Human genes 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 208000025747 Rheumatic disease Diseases 0.000 abstract 1
- 201000001880 Sexual dysfunction Diseases 0.000 abstract 1
- 102100037342 Substance-K receptor Human genes 0.000 abstract 1
- 102100033009 Tachykinin-3 Human genes 0.000 abstract 1
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 230000037396 body weight Effects 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 230000027288 circadian rhythm Effects 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 208000022821 personality disease Diseases 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 230000020341 sensory perception of pain Effects 0.000 abstract 1
- 231100000872 sexual dysfunction Toxicity 0.000 abstract 1
- 208000017520 skin disease Diseases 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000002455 vasospastic effect Effects 0.000 abstract 1
- 208000009935 visceral pain Diseases 0.000 abstract 1
- 238000004260 weight control Methods 0.000 abstract 1
- SETMGIIITGNLAS-UHFFFAOYSA-N spizofurone Chemical compound O=C1C2=CC(C(=O)C)=CC=C2OC21CC2 SETMGIIITGNLAS-UHFFFAOYSA-N 0.000 description 6
- 229950001870 spizofurone Drugs 0.000 description 6
- 235000013929 Psidium pyriferum Nutrition 0.000 description 4
- 244000236580 Psidium pyriferum Species 0.000 description 4
- 239000008476 aike Substances 0.000 description 3
- 241000283707 Capra Species 0.000 description 2
- 241000449533 Gabia Species 0.000 description 2
- POXUQBFHDHCZAD-MHTLYPKNSA-N (2r)-2-[(4s)-2,2-dimethyl-1,3-dioxolan-4-yl]-3,4-dihydroxy-2h-furan-5-one Chemical compound O1C(C)(C)OC[C@H]1[C@@H]1C(O)=C(O)C(=O)O1 POXUQBFHDHCZAD-MHTLYPKNSA-N 0.000 description 1
- REGZQZHKIFOMRK-LSCFUAHRSA-N (2r,3r,4s,5r)-2-[6-[(4-amino-3-iodophenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=C(I)C(N)=CC=C1CNC1=NC=NC2=C1N=CN2[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 REGZQZHKIFOMRK-LSCFUAHRSA-N 0.000 description 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
- 241000258740 Abia Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108700032845 Ala(2)- enkephalinamide-Met Proteins 0.000 description 1
- 241000566146 Asio Species 0.000 description 1
- UOACKFBJUYNSLK-XRKIENNPSA-N Estradiol Cypionate Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H](C4=CC=C(O)C=C4CC3)CC[C@@]21C)C(=O)CCC1CCCC1 UOACKFBJUYNSLK-XRKIENNPSA-N 0.000 description 1
- 235000010650 Hyssopus officinalis Nutrition 0.000 description 1
- 240000001812 Hyssopus officinalis Species 0.000 description 1
- 101150033824 PAA1 gene Proteins 0.000 description 1
- 241000514450 Podocarpus latifolius Species 0.000 description 1
- 241000168036 Populus alba Species 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 101000577937 Xenopus laevis Midkine-A Proteins 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940106943 azor Drugs 0.000 description 1
- 235000021158 dinner Nutrition 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- DIRFUJHNVNOBMY-UHFFFAOYSA-N fenobucarb Chemical compound CCC(C)C1=CC=CC=C1OC(=O)NC DIRFUJHNVNOBMY-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 230000021121 meiosis Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Otolaryngology (AREA)
- Hematology (AREA)
- Addiction (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Данное изобретение относится к замещенным производным 1-пиперидин-3-ил-4-пиперидин-4-ил-пиперазина, обладающим антагонистической активностью против нейрокинина, в частности, антагонистической активностью против NK1 и комбинированной антагонистической активностью против NК1/NК3 и против NK1/NK2/NK3, их получению, содержащим их композициям и их применению в качестве лекарственных средств для лечения шизофрении, тревожных состояний и депрессии, как противорвотного средства, при синдроме раздраженной толстой кишки, астме, нарушении мочеиспускания, болевых ощущениях. Соединения согласно изобретению могут быть представлены общей формулой (І) и включают в себя также их фармацевтически приемлемые аддитивные соли с кислотами или основаниями, их стереохимически изомерные формы, N-оксиды и их пролекарства, в которых все заместители определены в п. 1 формулы изобретения. Благодаря своей способности выступать в качестве антагонистов нейрокининов путем блокирования рецепторов нейрокининов, в частности, выступать в качестве антагонистов вещества Р, нейрокинина А и нейрокинина В за счет блокирования рецепторов NK1, NK2 и NK3, эти соединения могут применяться как лекарственные средства для профилактики и лечения состояний, опосредствованных тахикининами, таких как шизоаффективные нарушения, депрессии, тревожные состояния, расстройства, связанные со стрессом, расстройства сна, расстройства познавательной способности, нарушения, ведущие к изменению личности, расстройства, связанные с приемом пищи, нейродегенеративные заболевания, наркомания, половые расстройства, болевые синдромы, воспаления, аллергические состояния, рвота, желудочно-кишечные расстройства, в частности синдром раздраженной толстой кишки, кожные заболевания, вазоспастические заболевания, фиброзные и коллагеновые болезни, нарушения иммунной системы, ревматические заболевания, нарушения регуляции массы тела.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP0214835 | 2002-12-23 | ||
| PCT/EP2003/051035 WO2004056364A1 (en) | 2002-12-23 | 2003-12-17 | Substituted 1-piperidin-3-yl-4-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA83474C2 true UA83474C2 (ru) | 2008-07-25 |
Family
ID=32668701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA200505307A UA83474C2 (ru) | 2002-12-23 | 2003-12-17 | Замещенные производные 1-пиперидин-3-ил-4-пиперидин-4-ил-пиперазина и их применение в качестве антагонистов нейрокинина |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US7572786B2 (ru) |
| JP (1) | JP4660198B2 (ru) |
| KR (1) | KR101049075B1 (ru) |
| CN (1) | CN100482229C (ru) |
| AR (1) | AR042653A1 (ru) |
| AU (1) | AU2003300578B2 (ru) |
| CA (1) | CA2509088C (ru) |
| CL (1) | CL2003002722A1 (ru) |
| DE (1) | DE60317709T2 (ru) |
| EA (1) | EA008774B1 (ru) |
| ES (1) | ES2297275T3 (ru) |
| HR (1) | HRP20050554B1 (ru) |
| IL (1) | IL169337A (ru) |
| JO (1) | JO2485B1 (ru) |
| MX (1) | MXPA05006888A (ru) |
| MY (1) | MY134383A (ru) |
| NO (1) | NO331173B1 (ru) |
| NZ (1) | NZ541036A (ru) |
| PA (1) | PA8593201A1 (ru) |
| PL (1) | PL214705B1 (ru) |
| TW (1) | TWI327916B (ru) |
| UA (1) | UA83474C2 (ru) |
| WO (1) | WO2004056364A1 (ru) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY141736A (en) * | 2002-10-08 | 2010-06-15 | Elanco Animal Health Ireland | Substituted 1,4-di-piperidin-4-yi-piperazine derivatives and their use as neurokinin antagonists |
| EA015517B1 (ru) | 2004-04-13 | 2011-08-30 | Инсайт Корпорейшн | Производные пиперазинилпиперидина в качестве антагонистов хемокинового рецептора |
| GB0417702D0 (en) * | 2004-08-09 | 2004-09-08 | Merck Sharp & Dohme | New uses |
| ES2350647T3 (es) * | 2005-03-08 | 2011-01-25 | Janssen Pharmaceutica Nv | Derivados de diaza-espiro-[4.4]-nonano como antagonistas de neuroquininas (nk1). |
| US9505718B2 (en) * | 2013-03-15 | 2016-11-29 | Nanyang Technological University | 3-piperidone compounds and their use as neurokinin-1 (NK1) receptor antagonists |
| WO2015200594A2 (en) | 2014-06-25 | 2015-12-30 | Emory University | Methods of managing conditioned fear with neurokinin receptor antagonists |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY110227A (en) | 1991-08-12 | 1998-03-31 | Ciba Geigy Ag | 1-acylpiperindine compounds. |
| NZ321575A (en) * | 1995-10-30 | 1999-05-28 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives |
| TW531537B (en) * | 1995-12-27 | 2003-05-11 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives |
| FR2791346B3 (fr) * | 1999-03-25 | 2001-04-27 | Sanofi Sa | Nouveaux derives de morpholine, procede pour leur preparation et compositions pharmaceutiques les contenant |
| WO2001030348A1 (en) | 1999-10-25 | 2001-05-03 | Janssen Pharmaceutica N.V. | Use of substance p antagonists for influencing the circadian timing system |
| GB0025354D0 (en) * | 2000-10-17 | 2000-11-29 | Glaxo Group Ltd | Chemical compounds |
| GB2368098B (en) | 2000-10-20 | 2004-09-15 | Gw Pharmaceuticals Ltd | Secure dispensing of materials |
| US6642226B2 (en) * | 2001-02-06 | 2003-11-04 | Hoffman-La Roche Inc. | Substituted phenyl-piperidine methanone compounds |
| JP4389478B2 (ja) * | 2002-05-29 | 2009-12-24 | 田辺三菱製薬株式会社 | 新規ピペリジン誘導体 |
| MY141736A (en) * | 2002-10-08 | 2010-06-15 | Elanco Animal Health Ireland | Substituted 1,4-di-piperidin-4-yi-piperazine derivatives and their use as neurokinin antagonists |
| WO2004056772A1 (en) * | 2002-12-23 | 2004-07-08 | Janssen Pharmaceutica N.V. | Substituted 1,4-di-piperidin-4-yl-piperazine derivatives and their use as tachykinin antagonists |
| MXPA05013295A (es) * | 2003-06-10 | 2006-03-09 | Janssen Pharmaceutica Nv | Derivado sustituido de 1,4-piperidin-4-il-piperazina combinado con un analgesico opioideo y su uso para el tratamiento de dolor y efectos secundarios asociados con tratamientos de base opioidea. |
-
2003
- 2003-12-15 JO JO2003173A patent/JO2485B1/en active
- 2003-12-17 NZ NZ541036A patent/NZ541036A/en not_active IP Right Cessation
- 2003-12-17 CN CNB2003801070088A patent/CN100482229C/zh not_active Expired - Fee Related
- 2003-12-17 MX MXPA05006888A patent/MXPA05006888A/es active IP Right Grant
- 2003-12-17 PL PL376075A patent/PL214705B1/pl unknown
- 2003-12-17 KR KR1020057009752A patent/KR101049075B1/ko not_active Expired - Fee Related
- 2003-12-17 UA UAA200505307A patent/UA83474C2/ru unknown
- 2003-12-17 AU AU2003300578A patent/AU2003300578B2/en not_active Ceased
- 2003-12-17 ES ES03813610T patent/ES2297275T3/es not_active Expired - Lifetime
- 2003-12-17 DE DE60317709T patent/DE60317709T2/de not_active Expired - Lifetime
- 2003-12-17 EA EA200501040A patent/EA008774B1/ru not_active IP Right Cessation
- 2003-12-17 US US10/540,045 patent/US7572786B2/en not_active Expired - Fee Related
- 2003-12-17 JP JP2004561502A patent/JP4660198B2/ja not_active Expired - Fee Related
- 2003-12-17 CA CA2509088A patent/CA2509088C/en not_active Expired - Fee Related
- 2003-12-17 WO PCT/EP2003/051035 patent/WO2004056364A1/en not_active Ceased
- 2003-12-17 HR HRP20050554AA patent/HRP20050554B1/hr not_active IP Right Cessation
- 2003-12-19 MY MYPI20034910A patent/MY134383A/en unknown
- 2003-12-19 PA PA20038593201A patent/PA8593201A1/es unknown
- 2003-12-22 AR ARP030104779A patent/AR042653A1/es unknown
- 2003-12-22 TW TW092136344A patent/TWI327916B/zh not_active IP Right Cessation
- 2003-12-22 CL CL200302722A patent/CL2003002722A1/es unknown
-
2005
- 2005-06-21 IL IL169337A patent/IL169337A/en not_active IP Right Cessation
- 2005-07-22 NO NO20053598A patent/NO331173B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA83474C2 (ru) | Замещенные производные 1-пиперидин-3-ил-4-пиперидин-4-ил-пиперазина и их применение в качестве антагонистов нейрокинина | |
| De Trey et al. | Management of severe congenital laryngeal webs–a 12 year review | |
| Johns et al. | Pre and post-operative psychological functioning in younger and older children with microtia | |
| UA128156C2 (uk) | Пестицидний білок токсину, активний проти лускокрилих комах | |
| Senn et al. | Progenitor cells from the adult human inner ear | |
| PH12021550007A1 (en) | Thiadiazine derivatives | |
| Kuanar et al. | In vitro selection of turmeric somaclone resistant to Fusarium oxysporum f. sp. Zingiberi | |
| Leonhard et al. | Evaluation of combined growth media for in vitro cultivation of oropharyngeal biofilms on prosthetic silicone | |
| Bhardwaj | Resistance genes and adult plant rust resistance of released wheat varieties of India | |
| Kiverniti et al. | Taste disturbance after mastoid surgery: immediate and long-term effects of chorda tympani nerve sacrifice | |
| Céruse et al. | Laryngeal graft after total laryngectomy in humans: A SWiM analysis | |
| Campian et al. | There is a garden in her face | |
| Aibinder et al. | Safety and efficacy of shoulder arthroplasty following lower extremity periprosthetic joint infection | |
| Seller | Transplantation of anaemic mice of the W-series with haemopoietic tissue bearing marker chromosomes | |
| Yu-Ling et al. | Existence of extracellular calmodulin in the lower epidermis of the leaves of Vicia faba and its role in regulating stomatal movements | |
| UA83390C2 (ru) | Гексилкарбоксанилиды и способ борьбы с нежелательными микроорганизмами | |
| Visvanathan et al. | Swimming with a mastoid cavity: our experience with children | |
| Dronova et al. | Socialization Peculiarities of Minors from Disadvantaged Families | |
| Jittilaongwong | Experience of 9000 cases on lip reduction surgery in Thailand | |
| Grodstein et al. | Renal transplantation as a platform for teaching residents open vascular surgical techniques: Effects on early graft function | |
| Liddle | Forums go online | |
| Monaco | Mind the technological gap: the use of itcs amongst italian millennials in the pandemic era | |
| Shiells | Warsaw Conference on EU Enlargement and Related Flows of Labor and Capital | |
| Kim et al. | Variations of the Technique in Endoscopic Tympanoplasty | |
| Huang et al. | Spontaneous Portosystemic Shunt Ligation During Pediatric Liver Transplantation |